Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 15/20 | 0.67 |
| ▸ | MAOA | P21397 | 7/20 | 0.67 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.50 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3367221 | 1.00 | MAOB (0.67) | MAOBMAOAPOLBNPC1RAB9A | |
| SCHEMBL2441820 | 1.00 | MAOB (0.67) | MAOBMAOAPOLBNPC1RAB9A | |
| Hydrochloric Acid SCHEMBL3365163 | 0.99 | MAOB (0.66) | MAOBMAOAPOLBNPC1RAB9A | |
| Hydrochloric Acid SCHEMBL3365169 | 0.99 | MAOB (0.66) | MAOBMAOAPOLBNPC1RAB9A | |
| Hydrochloric Acid SCHEMBL3370177 | 0.99 | MAOB (0.66) | MAOBMAOAPOLBNPC1RAB9A | |
| SCHEMBL19863552 | 0.86 | MAOB (0.70) | MAOBMAOAPOLBNPC1RAB9A | |
| SCHEMBL18020923 | 0.86 | MAOB (0.70) | MAOBMAOAPOLBNPC1RAB9A | |
| SCHEMBL3365516 | 0.86 | NPC1 (0.71) | MAOBMAOAPOLBNPC1RAB9A | |
| SCHEMBL3365524 | 0.86 | NPC1 (0.71) | MAOBMAOAPOLBNPC1RAB9A | |
| SCHEMBL1380803 | 0.85 | RAB9A (0.77) | MAOBMAOAPOLBNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101142182-B | Method of preparation of pure 4-pyrrolidinophenylbenzyl ether derivatives as MAOB inhibitors | HOFFMANN LA ROCHE | 2012-06-06 | — | — | CN | claimed |
| EP-1861363-B1 | METHOD OF PREPARATION OF PURE 4-PYRROLIDINOPHENYLBENZYL ETHER DERIVATIVES AS MAOB INHIBITORS | HOFFMANN LA ROCHE (CH) | 2011-09-28 | — | — | EP | claimed |
| US-7501528-B2 | Method for preparing enantiomerically pure 4-pyrrolidino phenylbenzyl ether derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-03-10 | — | — | US | claimed |
| CN-101142182-A | Method of preparation of pure 4-pyrrolidinophenylbenzyl ether derivatives as MAOB inhibitors | HOFFMANN LA ROCHE (CH) | 2008-03-12 | — | — | CN | claimed |
| US-8227505-B2 | Method for preparing enantiomerically pure 4-pyrrolidino phenylbenzyl ether derivatives | HOFFMAN-LA ROCHE INC. (US) | 2012-07-24 | — | — | US | disclosed |
| CN-101142182-B | Method of preparation of pure 4-pyrrolidinophenylbenzyl ether derivatives as MAOB inhibitors | HOFFMANN LA ROCHE | 2012-06-06 | — | — | CN | disclosed |
| EP-1861363-B1 | METHOD OF PREPARATION OF PURE 4-PYRROLIDINOPHENYLBENZYL ETHER DERIVATIVES AS MAOB INHIBITORS | HOFFMANN LA ROCHE (CH) | 2011-09-28 | — | — | EP | disclosed |
| EP-1542970-B1 | PYRROLIDONE DERIVATIVES AS MAOB INHIBITORS | HOFFMANN LA ROCHE (CH) | 2010-06-30 | — | — | EP | disclosed |
| US-20090171100-A1 | METHOD FOR PREPARING ENANTIOMERICALLY PURE 4-PYRROLIDINO PHENYLBENZYL ETHER DERIVATIVES | HILDBRAND STEFAN | 2009-07-02 | — | — | US | disclosed |
| US-7501528-B2 | Method for preparing enantiomerically pure 4-pyrrolidino phenylbenzyl ether derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-03-10 | — | — | US | disclosed |
| CN-100400509-C | Pyrrolidone derivatives as MAOB inhibitors | HOFFMANN LA ROCHE (CH) | 2008-07-09 | — | — | CN | disclosed |
| CN-101142182-A | Method of preparation of pure 4-pyrrolidinophenylbenzyl ether derivatives as MAOB inhibitors | HOFFMANN LA ROCHE (CH) | 2008-03-12 | — | — | CN | disclosed |
| US-7151111-B2 | 4-pyrrolidino-phenyl-benzyl ether derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-12-19 | — | — | US | disclosed |
| US-20060211868-A1 | Method for preparing enantiomerically pure 4-pyrrolidino phenylbenzyl ether derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2006-09-21 | — | — | US | disclosed |
| CN-1681778-A | Pyrrolidone derivatives as MAOB inhibitors | HOFFMANN LA ROCHE (CH) | 2005-10-12 | — | — | CN | disclosed |
| EP-1542970-A1 | PYRROLIDONE DERIVATIVES AS MAOB INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2005-06-22 | — | — | EP | disclosed |
| US-20040116707-A1 | 4-Pyrrolidino-phenyl-benzyl ether derivatives | HOFFMANN-LA ROCHE INC. | 2004-06-17 | — | — | US | disclosed |
| WO-2004026825-A1 | PYRROLIDONE DERIVATIVES AS MAOB INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090171100-A1 | METHOD FOR PREPARING ENANTIOMERICALLY PURE 4-PYRROLIDINO PHENYLBENZYL ETHER DERIVATIVES | CYP4B1, CYP3A4, PAH | MAOB 227/4885MAOA 2270/4885POLB 682/4885 |
| US-20060211868-A1 | Method for preparing enantiomerically pure 4-pyrrolidino phenylbenzyl ether derivatives | CYP4B1, CYP3A4, PAH | MAOB 227/4885MAOA 2270/4885POLB 682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.